Your browser doesn't support javascript.
loading
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
Nasser, Azmi; Liranso, Tesfaye; Adewole, Toyin; Fry, Nicholas; Hull, Joseph T; Chowdhry, Fatima; Busse, Gregory D; Melyan, Zare; Cutler, Andrew J; Findling, Robert L; Schwabe, Stefan.
Affiliation
  • Nasser A; Supernus Pharmaceuticals, Inc., Rockville, MD, USA. Electronic address: anasser@supernus.com.
  • Liranso T; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
  • Adewole T; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
  • Fry N; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
  • Hull JT; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
  • Chowdhry F; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
  • Busse GD; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
  • Melyan Z; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
  • Cutler AJ; SUNY Upstate Medical University, and Neuroscience Education Institute, Lakewood Ranch, FL, USA.
  • Findling RL; School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Schwabe S; Supernus Pharmaceuticals, Inc., Rockville, MD, USA.
Clin Ther ; 43(4): 684-700, 2021 04.
Article in En | MEDLINE | ID: mdl-33750646

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Attention Deficit Disorder with Hyperactivity / Central Nervous System Stimulants Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Clin Ther Year: 2021 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Attention Deficit Disorder with Hyperactivity / Central Nervous System Stimulants Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Clin Ther Year: 2021 Document type: Article Country of publication: United States